A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Rilotumumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms RILOMET-1
- Sponsors Amgen
- 13 Jan 2022 This trial has been completed in Romania (End Date: 07 Aug 2015), according to European Clinical Trials Database record.
- 21 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
- 25 Sep 2017 Results published in the Lancet Oncology